<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>drugs | ALS | MND</title><link>/tag/drugs/</link><atom:link href="/tag/drugs/index.xml" rel="self" type="application/rss+xml"/><description>drugs</description><generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Wed, 17 Feb 2021 00:00:00 +0000</lastBuildDate><image><url>/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png</url><title>drugs</title><link>/tag/drugs/</link></image><item><title>Masitinib</title><link>/alternative-treatment/masitinib/</link><pubDate>Wed, 17 Feb 2021 00:00:00 +0000</pubDate><guid>/alternative-treatment/masitinib/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;p>Masitinib is an oral treatment designed to block the activity of multiple cell types — including macrophages, neutrophils, mast cells, and Schwann cells — involved in the inflammatory and neurodegenerative processes marking ALS. It does so through the activity of proteins called tyrosine kinases.&lt;sup id="fnref:1">&lt;a href="#fn:1" class="footnote-ref" role="doc-noteref">1&lt;/a>&lt;/sup>&lt;/p>
&lt;p>Check &lt;a href="https://www.ab-science.com/science/masitinib-in-neurodegenerative-disorders/" target="_blank" rel="noopener">AB Science&lt;/a> page to know more.&lt;/p>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h4 id="2019---add-on-masitinib-slows-progression-of-als-final-phase-23-trial-results-showhttpswwwtandfonlinecomdoifull1010802167842120191632346">&lt;a href="https://www.tandfonline.com/doi/full/10.1080/21678421.2019.1632346" target="_blank" rel="noopener">2019 - Add-on Masitinib Slows Progression of ALS, Final Phase 2/3 Trial Results Show&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./masitinib_as_an_add_on_therapy_to_riluzole_in_patients_with_als.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>Masitinib in combination with Rilutek (riluzole) slows functional decline of patients with amyotrophic lateral sclerosis (ALS) who have a typical disease progression, according to the final report of AB Science‘s Phase 2/3 clinical trial.&lt;/p>
&lt;p>At 11 months of treatment with the combo, the rate of disability progression was reduced by 27%, as compared to a placebo plus Rilutek. In contrast, patients who have a faster disease worsening do not benefit as much from adding masitinib to their treatment.&lt;/p>
&lt;/blockquote>
&lt;p>&lt;img src="./masitinib_phaseII.png" alt="PhaseII results">&lt;/p>
&lt;section class="footnotes" role="doc-endnotes">
&lt;hr>
&lt;ol>
&lt;li id="fn:1" role="doc-endnote">
&lt;p>from &lt;a href="https://alsnewstoday.com/news-posts/2020/04/03/fda-clears-ab-science-to-open-phase-3-trial-of-masitinib-add-on-als-treatment/" target="_blank" rel="noopener">ALS News Today&lt;/a> &lt;a href="#fnref:1" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;/ol>
&lt;/section></description></item><item><title>Research - Seneca NSI-566</title><link>/alternative-treatment/nsi-566/</link><pubDate>Sat, 27 Jun 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/nsi-566/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;p>NSI-566 is an investigational neural stem cell therapy that uses human spinal cord stem cells (HSSCs). Stem cells are unique in that they have the capacity to differentiate into many types of specialized cells during development.&lt;/p>
&lt;p>When injected into the spinal cord, NSI-566 differentiates into types of neurons found in adults. They surround and support motor neurons damaged by ALS, by integrating into the neural network and forming connections (synapses) with the patient’s own neurons. They also secrete certain molecules that promote motor neuron growth and survival.&lt;/p>
&lt;p>Seneca Bio received orphan designation by the FDA for NSI-566 in ALS. NSI-566 was evaluated in Phase 1 and Phase 2 safety studies in 30 patients. The data showed that the intraspinal transplantation of the cells was safe and well tolerated. Subjects from both the Phase 1 and Phase 2 studies continue to be monitored for long-term follow-up evaluations.&lt;/p>
&lt;p>You can check Seneca &lt;a href="https://senecabio.com/pipeline/nsi-566.html" target="_blank" rel="noopener">product pipeline&lt;/a>&lt;/p>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h3 id="2020---als-news-today-nsi-566httpsalsnewstodaycomnsi-566">&lt;a href="https://alsnewstoday.com/nsi-566/" target="_blank" rel="noopener">2020 - ALS news today: NSI-566&lt;/a>&lt;/h3>
&lt;blockquote>
&lt;p>When injected into the spinal cord, these fetal stem cells differentiate into the kind of neurons that exist in the adult body. They surround and support the impaired motor neurons in ALS by integrating into the neural network and forming connections (synapses) with the patient’s own neurons&lt;/p>
&lt;/blockquote>
&lt;h3 id="2020---als-news-today-seneca-is-now-moving-to-phase-iiihttpsalsnewstodaycom20200413potential-stem-cell-therapy-nsi-566-moving-into-phase-3-trial-seneca-says">&lt;a href="https://alsnewstoday.com/2020/04/13/potential-stem-cell-therapy-nsi-566-moving-into-phase-3-trial-seneca-says/" target="_blank" rel="noopener">2020 - ALS news today: Seneca is now moving to Phase III&lt;/a>&lt;/h3>
&lt;blockquote>
&lt;p>Seneca Biopharma announced that work is underway to advance NSI-566, its leading stem cell treatment candidate, into a Phase 3 study in people with amyotrophic lateral sclerosis (ALS).&lt;/p>
&lt;p>The decision followed a meeting with the US Food and Drug Administration (FDA), and is supported by data collected from a Phase 1 (NCT01348451) and Phase 2 (NCT01730716) clinical trial.&lt;/p>
&lt;/blockquote>
&lt;h3 id="new-data-recently-developed-from-the-p1p2-study-regarding-insights-into-potential-for-efficacyhttpssenecabiocomnews-mediapress-releasesdetail244neuralstem-announces-publication-of-long-term-follow-uphtml">&lt;a href="https://senecabio.com/news-media/press-releases/detail/244/neuralstem-announces-publication-of-long-term-follow-up.html" target="_blank" rel="noopener">New data recently developed from the P1/P2 study regarding insights into potential for efficacy&lt;/a>&lt;/h3>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./2018-05-03_Neuralstem_Announces_Publication_of_Long_Term_244.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>Post-hoc comparison of combined cohorts from Phase 1 and 2 trials vs. historical controls revealed statistically significant
difference in scores in functional status and in a composite statistic combining survival and functional status in subjects receiving
human spinal cord-derived neural stem cells.&lt;br>
Study provides validation for additional trials to evaluate the benefit of neural stem cells in ALS patients&lt;/p>
&lt;/blockquote>
&lt;h3 id="2018---neuralstem-nsi-566-and-nsi-189httpswwwyoutubecomwatchvfbqhde0vnmat213s">&lt;a href="https://www.youtube.com/watch?v=fBQHDE0vnmA&amp;amp;t=213s" target="_blank" rel="noopener">2018 - Neuralstem NSI-566 and NSI-189&lt;/a>&lt;/h3>
&lt;div style="position: relative; padding-bottom: 56.25%; height: 0; overflow: hidden;">
&lt;iframe src="https://www.youtube.com/embed/fBQHDE0vnmA" style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border:0;" allowfullscreen title="YouTube Video">&lt;/iframe>
&lt;/div></description></item></channel></rss>